Pfizer 2011 Annual Review | Pfizer: the world's largest research-based pharmaceutical company READ
THE CEO
LETTER

At Our Core:

Determination.
Innovation. Humanity.

Leading in the business of innovative life science, we remain focused on what matters: the health needs of people and how best to meet them.

Determination.

We are dedicated, as people and as a business, to leading the research-based biopharmaceutical industry in productive, responsible and beneficial life science.

Our Imperatives

As a leader in this vital industry, our purpose is clear: applying innovative science to improve health and well-being. The actions we take are crucial, not only to our success as a business, but also to the lives of those who count on us to succeed.

Read more
close

Our Imperatives

As a leader among biopharmaceutical businesses, our purpose is clearly stated: apply innovative science to improve health and well-being. Success here is crucial, first and foremost to patients awaiting new treatments, but also to those who invest in us and work with us.

We are focusing on four overarching priorities—we call them "imperatives"—to enable us to position Pfizer for success and differentiate the company from our competitors.

Read More About Our Imperatives in the Letter to Our Stakeholders.

Innovation.

We focus collaborative, breakthrough science on addressing unmet needs with medicines and vaccines that profoundly affect health and well-being.

play  

Precision Medicine —
The Xalkori Story

The leading edge of innovation in biopharmaceuticals may be precision medicines—therapies focused sharply on a disease caused by a very specific gene deficiency or mutation. Xalkori, for certain types of lung cancer, vaulted Pfizer into prominence in precision medicine in 2011.

Read more
close

Precision Medicine — The Xalkori Story

Increasing R&D Productivity

Research-based pharmaceutical companies are facing key challenges today due to increasing costs, long cycle times, high late-stage attrition, and technological and genomic breakthroughs that have increased R&D complexity. In 2011, we made significant changes in our R&D model to facilitate the flow of important medicines and vaccines. We launched a three-phase, multiyear effort to accelerate Pfizer's R&D strategy and create an engine for sustainable innovation (ESI).

2011 stands as a banner year for our reinvigorated pipeline. A number of new medicines and indications were approved, underscoring our ability to channel science to patient benefit. And as the recently fast-tracked and approved Xalkori (crizotinib) in the U.S. attests, our commitment to Precision Medicine holds promise for patients and our business.

A new, more expansive approach to external collaboration is essential to our R&D strategy. Our Centers for Therapeutic Innovation embed small groups of Pfizer scientists within leading academic medical centers, in the interest of shaping the future and speeding our progress.

2011 Highlights
  • Eliquis (apixaban) approved in Europe for the prevention of venous thromboembolism (blood clots) in joint replacement patients; accepted for review in Europe and the U.S. for stroke prevention in patients with atrial fibrillation.
    Eliquis (apixaban) Approved

    Eliquis (apixaban) approved in Europe for the prevention of venous thromboembolism (blood clots) in joint replacement patients; accepted for review in Europe and the U.S. for stroke prevention in patients with atrial fibrillation.

  • Vyndaqel (tafamidis) was approved in the European Union in November 2011 for the treatment of transthyretin familial amyloid polyneuropathy (TTR-FAP) in adult patients with stage 1 symptomatic polyneuropathy. This approval represents a major advance as Vyndaqel is the first and only medication to delay neurologic impairment for patients suffering from this rare, progressive and nearly always fatal neurodegenerative disease, estimated to affect 8,000 people worldwide.
    Vyndaqel (tafamidis) Approved in EU to Combat Rare Disease

    Vyndaqel (tafamidis) was approved in the European Union in November 2011 for the treatment of transthyretin familial amyloid polyneuropathy (TTR-FAP) in adult patients with stage 1 symptomatic polyneuropathy. This approval represents a major advance as Vyndaqel is the first and only medication to delay neurologic impairment for patients suffering from this rare, progressive and nearly always fatal neurodegenerative disease, estimated to affect 8,000 people worldwide.

  • Prevnar 13/Prevenar 13 approved for various indications in adults 50 years and older in the United States, European Union, Australia and more than 10 other countries. Prevenar 13 is already approved for infants and young children in more than 110 countries.
    Prevnar 13/Prevenar 13 Approved for Adults 50 Years and Older

    Prevnar 13/Prevenar 13 approved for various indications in adults 50 years and older in the United States, European Union, Australia and more than 10 other countries. Prevenar 13 is already approved for infants and young children in more than 110 countries.

    For more information visit Pfizer Pharmaceutical Products

  • Launched the industry's first-ever virtual trial using mobile and Web-based technology to collect data from remote locations. The pilot began in California and will eventually expand to include 600 patients in remote locations across 10 states in the U.S. This approach allows patients suffering from overactive bladder to participate in the study and avoid travelling to clinics during the trial.
    First Virtual Clinical Trial

    Launched Pfizer's first-ever virtual trial using mobile and Web-based technology to collect data from remote locations. The pilot debuted in California and will eventually expand to include 600 patients in remote locations across 10 states in the U.S. It is designed to assess the safety and efficacy of Detrol LA, a treatment for overactive bladder.

  • Advil became the No.1 brand in its category in North America and the No. 1 selling OTC analgesic brand in the world
    Advil No. 1

    Advil became the No.1 brand in its category in North America—and the No. 1 selling OTC analgesic brand in the world

  • Safe Use of Medicines, a 'speaking book,' launched in Uganda and Senegal. Designed specifically for sub-Saharan Africa, the book requires no understanding of written words. It features a combination of colorful pictures, text and sound. The book is available in both English and French and the recorded voices are local. Each page has a button to press to hear the text read out loud.
    Speaking Book Illuminates Safe Use of Medicines

    "Safe Use of Medicines," a 'speaking book,' launched in Uganda and Senegal. Designed specifically for sub-Saharan Africa, the book requires no understanding of written words. It features a combination of colorful pictures, text and sound. The book is available in both English and French and the recorded voices are local. Each page has a button to press to hear the text read out loud.

Humanity.

We embrace the business of innovative life science because of what it can do, and what we are doing, to improve lives all around the world.

play  

Life Lessons

Life is teaching us many things, encouraging us to embrace health and well-being at every stage of life, and to foster a new age of aging well.

Read more
close

Life Lessons

Earning Respect Through Sensible Business

Our efforts to help humanity must also make business sense. And they do. Improving health and well-being is our business. Working to raise standards of health care, improve access and help support economic development around the world creates more demand for what we offer and helps to open new markets—and new opportunities in established ones. Finding, creating and adapting business models that can work in developing and underserved markets hones our skills, expands our impact and grows our business, while bringing essential health care and services to people in need.

Patient safety is absolutely integral to our success and to how we organize all our business processes. We work to ensure safety in everything we do with patients, from initial human trials to post-marketing studies, and encompassing the complete life cycle of our medicines from initial development through off-patent and generic phases. We take a long view of productivity, taking into account environmental effects, and we are working hard to reduce our environmental footprint even as we grow and reach millions of new people.

This is all in support of building a sustainable global enterprise that meets the needs of all our stakeholders, year after year.

2011 Highlights
  • Under the auspices of the GAVI Alliance's Advance Market Commitment (AMC) for pneumococcal vaccines, Pfizer will now supply up to 480 million doses of Prevenar 13 through 2023. This broadens and extends our commitment to help protect millions of infants and young children in the developing world from pneumococcal disease, the leading cause of vaccine-preventable death in young children.
    Bringing Prevenar 13 to Children in Need Worldwide

    Under the auspices of the GAVI Alliance's Advance Market Commitment (AMC) for pneumococcal vaccines, Pfizer will now supply up to 480 million doses of Prevenar 13 through 2023. This broadens and extends our commitment to help protect millions of infants and young children in the developing world from pneumococcal disease, the leading cause of vaccine-preventable death in young children.

  • Received an award from China's Ministry of Commerce Executive Committee of Foreign Investment Companies, for Pfizer's support of the Chinese Foundation for Lifeline Express, a foundation that provides free cataract operations.
    Pfizer's Support of Lifeline Express Recognized in China

    Received an award from China's Ministry of Commerce Executive Committee of Foreign Investment Companies, for Pfizer's support of the Chinese Foundation for Lifeline Express, a foundation that provides free cataract operations.

  • Pfizer has harnessed the power of the wind at its global supply facility in Puurs, Belgium. The 45-story wind turbine will supply 5,100 megawatts per year, or 12 percent of the electricity consumed by the Puurs site, reducing the production unit's annual carbon footprint by 2,040 tons. The wind turbine's life cycle is about 20 years, and will pay for itself in less than four years.
    Wind Turbine Powering Puurs, Belgium

    Pfizer has harnessed the power of the wind at its global supply facility in Puurs, Belgium. The 45-story wind turbine will supply 5,100 megawatts per year, or 12 percent of the electricity consumed by the Puurs site, reducing the production unit's annual carbon footprint by 2,040 tons. The wind turbine's life cycle is about 20 years, and will pay for itself in less than four years.

  • Through the efforts of Pfizer's Green Chemistry teams across the globe, Lyrica is now greener?less energy is used resulting in an 80 percent reduction in carbon dioxide emissions. Pregabalin, the active ingredient in Lyrica, is made using biocatalysis (nature's enzymes), less solvents and fewer raw materials.
    Greener Process for Lyrica

    Through the efforts of Pfizer's Green Chemistry teams across the globe, Lyrica is now greener?less energy is used resulting in an 80 percent reduction in carbon dioxide emissions. Pregabalin, the active ingredient in Lyrica, is made using biocatalysis (nature's enzymes), less solvents and fewer raw materials.

  • We have recently launched a folding carton using recycled cardboard, one of the eco-friendly packaging initiatives at Pfizer that help reduce the company's environmental footprint. The new packaging will gradually become standard for all Norvasc packs coming out of the Illertissen, Germany, site with the intent to have all products packaged at the site (Celebrex, Cardura, Relpax, Toviaz, Mono Mack, Champix, Zeldox and Vfend) use environmentally friendly packaging.
    Pfizer's Global Health Partnerships honored with 2011 "Citizens" Award

    The Corporate Citizenship Awards given by the U.S. Chamber of Commerce Business Civic Leadership Center honor excellence in corporate citizenship and civic leadership. Pfizer's Global Health Partnership program was recognized as "Best International Ambassador" for its efforts to combat noncommunicable diseases by strengthening healthcare systems and infrastructure to support cancer and tobacco control efforts in 46 countries primarily in the developing world.